Comparison of Efficacy between Myo-Inositol versus Metformin in Women with Polycystic Ovary Syndrome

Nurmeen Latif , Seema Rajar, Mehreen Yousuf, Sadaf Imtiaz, Sidrah Abbas, Zara Jamali


Objective: To compare the effectiveness of myo-inositol versus metformin in treating women with polycystic ovary syndrome.
Study Design: Cross-sectional study.
Place and Duration of Study: The study was carried out at the Department of Gynae Unit II, Dr. Ruth. K.M. Pfau Civil Hospital Karachi, Pakistan from 7th February 2019 to 6th August 2019.
Methods: All eligible patients who visited the hospital were enrolled. The group-Aincluded females who received myo-inositol (n=35), whereas the group-B included females who received metformin (n=35). Females in the myo-inositol group were administered 1 gram of myo-inositol twice daily, while those in the metformin group were administered 500 mg of metformin twice daily. Regular follow-up visits were scheduled every two months, and the efficacy of the treatment was assessed after six months. Efficacy was evaluated in terms of the normalization of menstrual cycles and the achievement of ovulation.
Results: The mean age in the myo-inositol and metformin groups was 23.92±3.70 and 23.68±4.23, respectively. The mean weight in the myoinositol and metformin groups was 59.23±2.07 and 61.79±5.92, respectively. Notably, the efficacy rates for the myo-inositol and metformin groups were 68.57% and 20%, respectively with p-value=0.0001.
Conclusion: Myo-inositol was found to demonstrate significant superiority over metformin in the treatment of polycystic ovary syndrome.

Keywords: Hyperandrogenism, Metformin, Menstrual Cycle, Polycystic Ovary Syndrome.

How to cite this: Latif N, Rajar S, Yousuf M, Imtiaz S, Abbas S, Jamali Z. Comparison of Efficacy Between Myo-Inositol versus Metformin in Women with Polycystic Ovary Syndrome. Life and Science. 2024; 5(1): 48-53. doi:

Read PDF